Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study

Annals of Oncology

Volumn 21, Issue 4, 2009, Pages 787-794

  Cwikla, J B ^a   Sankowski, A ^a   Seklecka, N ^a   Buscombe, J R ^b   Nasierowska Guttmejer, A ^a   Jeziorski, K G ^a,c   Mikolajczak, R ^d   Pawlak, D ^d   Stepien, K ^a   Walecki, J ^a,e  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Clinical and radiological response; DOTATATE Y 90 therapy; GEP NET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID[DEXTRO PHENYLALANYLTYROSINE]OCTREOTATE Y 90; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE; ONDANSETRON; STREPTOZOCIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLUSHING; GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA; GASTROINTESTINAL SURGERY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 77951940409     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp372     Document Type: Article

References (31)

1. Caplin ME, Buscombe JR, Hilson AJ et al. Carcinoid tumour. Lancet 1998; 352: 799-805.
2. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumours)? J Natl Cancer Inst 2000; 92: 179-181.
3. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993; 32: 225-229.
4. Ducreux M, Ruszniewski P, Chayvialle JA et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276-3281.
5. 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237: 718-726.
6. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
7. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-431.
8. 111In- pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44: 1-6.
9. Plöckinger U, Rindi R, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
10. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
11. Kwekkeboom DJ, Bakker WH, Kam BL et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30: 417-422.
12. 3]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-1351.
13. Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatine analog [177Lu-DOTA0Tyr3]octreotate: toxicity, efficacy and survival. J Clin Oncol 2008; 26: 2124-2130.
14. 111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-1325.
15. 111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005; 46: 1561-1569.
16. 99mTc-[HYNIC-TATE] in identifying sites of disease in patients with proven GEP-NET tumors. J Nucl Med 2008; 49: 1060-1065.
17. Karnofsky DA, Abelmann WH, Craver LF et al. The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1948; 1: 634-656.
18. De Jong M, Valkema R, Jamar F et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140.
19. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-1447.
20. Breeman WA, de Jong M, Kwekkeboom DJ et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28: 1421-1429.
21. Kloeppel G, Rindi G, Anlauf M et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumours. Virchows Arch 2007; 451: S9-S27.
22. Eriksson B, Kloeppel G, Krenning EP et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19.
23. 90Y-DOTATOC. J Nucl Med 2002; 43: 610-616.
24. 90Y DOTA-TATE) in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004; 31 (Suppl S238).
25. Baum RP, Wehrmann C, Zachert C et al. Long-term results of peptide receptor radionuclide therapy (PRRT): 5-year follow-up of 1,150 courses in 360 patients with progressive, somatostatin receptor positive neuroendocrine tumors in one clinical center. J Nucl Med 2007; 48 (Suppl 37P)
26. Chinol M, Bodei L, Cremonesi M et al. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32: 141-147.
27. Michaelis LC, Ratain MJ. Measuring response in post-RECIST world: from black and white to shades of gray. Nat Rev Cancer 2006; 6: 409-414.
28. Forrer F, Waldherr C, Maecke HR et al. Targeted radionuclide therapy with 90Y- DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006; 26(1B): 703-707.
29. Pauwels S, Barone R, Walrand S et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labelled somatostatin analogues. J Nucl Med 2005; 46 (Suppl 1): 92S-98S.
30. 90Y- DOTATOC. Eur J Nucl Med 2001; 28: 1552-1554.
31. Valkema R, Pauwels SA, Kvols LK et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA, Tyr3-Octreotide and 177Lu-DOTA, Tyr3-Octreotate. J Nucl Med 2005; 46: 83S-91S.